OncoMatch/Clinical Trials/NCT07082803
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Is NCT07082803 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including TLN-121 and zeprumetostat (TLN-254) for lymphoma.
Treatment: TLN-121 · zeprumetostat (TLN-254) — The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Central Nervous System Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Large B-cell lymphoma (LBCL)...following at least 2 prior lines of therapy.
Must have received: systemic therapy
FL grade 1-3a that requires treatment following at least 2 prior lines of therapy.
Must have received: systemic treatment regimen
Peripheral T-cell lymphoma (PTCL) subtypes that have relapsed after, or not responded to at least 1 prior systemic treatment regimen
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Medicine Cancer Center · Palo Alto, California
- The START Center for Cancer Care - Midwest · Grand Rapids, Michigan
- Washington University School of Medicine · St Louis, Missouri
- Memorial Sloan Kettering Cancer Center · New York, New York
- Weill Cornell Medicine - New York Presbyterian Hospital · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07082803 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy and systemic therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify